Fresenius Medical Care FMS
$20.44 +$0.31 (+1.54%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $20.44 0.00%
Open$20.49
Prev close$20.13
Day range$20.38 – $20.72
Volume1.34M
Market cap$10.61B
P/E (TTM)12.5
Dividend yield4.14%
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in EUR
Revenue€4.94B+1.1% YoY
Operating profit€473.05M-6.0% YoY
Net profit€224.80M-31.3% YoY
Diluted EPS€0.31-35.1% YoY
Free cash flow€559.59M+1.9% YoY
Operating cash flow€797.56M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin26.5%
Operating margin10.0%
Net margin4.2%
Return on equity6.4%
Return on assets2.6%
Return on invested capital4.6%
Current ratio0.99
Liabilities / assets56.3%
Cash & investments€1.48B
Total debt€10.30B
Net cash (debt)-€8.82B
Free cash flow / sales9.2%
Where the revenue comes from
Quarter 2026/Q3
By business line
This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.
Income statement
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Revenue as Reported | €4.94B | €4.86B | €4.61B | €19.63B | €5.07B |
| Total Operating Revenue | €4.94B | €4.86B | €4.61B | €19.63B | €5.07B |
| Cost of Revenue | €3.66B | €3.55B | €3.43B | €14.60B | €3.68B |
| Gross Profit | €1.28B | €1.31B | €1.18B | €5.03B | €1.39B |
| Operating Expense | €802.32M | €772.72M | €803.94M | €3.20B | €823.23M |
| Selling and Admin Expenses | €743.60M | €736.01M | €748.94M | €3.03B | €784.62M |
| -Selling & Marketing Expense | €155.79M | – | €147.54M | €618.14M | €156.46M |
| -General & Admin Expense | €587.82M | – | €601.40M | €2.41B | €628.16M |
| Research & Development | €41.40M | €39.63M | €38.31M | €157.98M | €38.63M |
| Other Operating Expenses | €17.32M | -€2.93M | €16.69M | €11.40M | -€19,000.00 |
| Operating Profit | €473.05M | €537.27M | €375.56M | €1.83B | €565.14M |
| Net Non-Operating Interest Income (Expense) | -€81.46M | -€82.86M | -€78.68M | -€314.80M | -€85.40M |
| Non-Operating Interest Income | €16.05M | €14.70M | €14.62M | €69.61M | €13.62M |
| Non-Operating Interest Expense | €97.51M | €97.55M | €93.30M | €384.41M | €99.02M |
| Other Income (Expense) | -€88.96M | -€71.41M | -€89.36M | €212,000.00 | €28.72M |
| Gain on Sale of Security | -€8.71M | -€10.70M | -€10.12M | -€120.83M | -€36.88M |
| Earnings from Equity Interest | €18.16M | -€41.26M | €41.32M | €181.37M | €41.69M |
| Special Income (Charges) | -€98.41M | -€19.46M | -€120.56M | -€60.32M | €23.91M |
| -Gain on Sale Of Business | -€99.86M | -€16.34M | -€134.99M | -€61.32M | €22.43M |
| -Gain on Sale of Property/Plant/Equipment | €1.44M | -€3.12M | €14.43M | €993,000.00 | €1.49M |
| Pretax Profit | €302.63M | €383.00M | €207.52M | €1.51B | €508.46M |
| Tax | €77.84M | €89.83M | €42.75M | €320.97M | €106.44M |
| Net Profit | €224.80M | €293.17M | €164.76M | €1.19B | €402.02M |
| Profit from Continuing Operations | €224.80M | €293.17M | €164.76M | €1.19B | €402.02M |
| Minority Interests | €65.02M | €74.79M | €47.23M | €212.90M | €74.94M |
| Net Income to Parent Company | €159.78M | €218.38M | €117.53M | €978.37M | €327.08M |
| Net Income to Common Stockholders | €159.78M | €218.38M | €117.53M | €978.37M | €327.08M |
| Basic EPS | €0.31 | €0.41 | €0.22 | €1.68 | €0.57 |
| Diluted EPS | €0.31 | €0.41 | €0.22 | €1.68 | €0.57 |
| Dividend Per Share | €0.00 | €0.75 | €0.00 | €0.72 | €0.00 |
Balance sheet
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Total Assets | €31.45B | €31.29B | €31.47B | €31.00B | €31.00B |
| Total Current Assets | €7.84B | €7.69B | €8.11B | €7.90B | €7.90B |
| Cash and Cash Equivalents & Short-Term Investments | €1.48B | €1.45B | €1.62B | €1.82B | €1.82B |
| -Cash and Cash Equivalents | €1.10B | €1.06B | €1.24B | €1.58B | €1.58B |
| -Short Term Investments | €383.99M | €388.10M | €384.20M | €238.77M | €238.77M |
| Receivables | €3.45B | €3.47B | €3.72B | €3.66B | €3.66B |
| -Accounts Receivable | €3.31B | €3.35B | €3.58B | €3.16B | €3.16B |
| -Taxes Receivable | €101.09M | €85.45M | €103.89M | €290.39M | €290.39M |
| -Due from Related Parties Current | €34.69M | €29.57M | €29.50M | €32.68M | €32.68M |
| Inventory | €2.41B | €2.33B | €2.30B | €2.14B | €2.14B |
| Other Current Assets | €493.61M | €442.88M | €466.17M | €211.81M | €211.81M |
| Total Non-Current Assets | €23.61B | €23.60B | €23.36B | €23.10B | €23.10B |
| Net PPE | €6.38B | €6.43B | €6.44B | €6.50B | €6.50B |
| -Gross PPE | €6.38B | €6.43B | €6.44B | €17.68B | €17.68B |
| Investments and Advances | €1.37B | €1.36B | €1.33B | €1.32B | €1.32B |
| -Available for Sale Securities | €687.91M | €695.53M | €628.92M | €357.15M | €357.15M |
| -Long Term Equity Investment | €678.32M | €660.69M | €701.40M | €663.65M | €663.65M |
| Non Current Accounts Receivables | €137.00M | €150.02M | €95.90M | – | – |
| Goodwill and Other Intangible Assets | €15.27B | €15.25B | €15.10B | €14.83B | €14.83B |
| -Goodwill | €14.02B | €13.97B | €13.85B | €13.57B | €13.57B |
| -Other Intangible Assets | €1.26B | €1.28B | €1.26B | €1.25B | €1.25B |
| Non-Current Deferred Assets | €301.26M | €273.62M | €249.49M | €236.55M | €236.55M |
| Other Non-Current Assets | €145.12M | €146.45M | €137.49M | €218.23M | €218.23M |
| Total Liabilities | €17.69B | €17.76B | €17.26B | €16.72B | €16.72B |
| Total Current Liabilities | €7.91B | €7.18B | €6.73B | €6.25B | €6.25B |
| Payables | €1.19B | €1.12B | €1.04B | €1.11B | €1.11B |
| -Accounts Payable | €927.60M | €891.84M | €890.43M | €835.55M | €835.55M |
| -Total Tax Payable | €266.21M | €232.85M | €151.79M | €278.84M | €278.84M |
| Short-Term Debt and Capital Lease Obligation | €2.97B | €2.33B | €2.39B | €2.20B | €2.20B |
| -Current Debt | €2.39B | €1.74B | €1.80B | €1.61B | €1.61B |
| -Current Capital Lease Obligation | €585.18M | €583.86M | €593.28M | €584.29M | €584.29M |
| Current Provisions | €383.20M | €404.51M | €367.55M | €431.37M | €431.37M |
| Other Current Liabilities | €3.35B | €3.32B | €2.93B | €1.44B | €1.44B |
| Total Non-Current Liabilities | €9.79B | €10.58B | €10.53B | €10.47B | €10.47B |
| Long Term Accounts Payable and Other Payables | €111.67M | €120.08M | €112.35M | €108.74M | €108.74M |
| Long Term Debt and Capital Lease Obligation | €7.91B | €8.64B | €8.64B | €8.60B | €8.60B |
| -Long Term Debt | €5.15B | €5.82B | €5.74B | €5.69B | €5.69B |
| -Long Term Capital Lease Obligation | €2.76B | €2.81B | €2.90B | €2.91B | €2.91B |
| Non-Current Liabilities | €231.74M | €198.45M | €182.53M | €173.35M | €173.35M |
| Non-Current Deferred Liabilities | €658.38M | €673.10M | €703.29M | €699.28M | €699.28M |
| Employee Benefits | €507.22M | €578.25M | €574.20M | €679.39M | €679.39M |
| Other Non-Current Liabilities | €365.17M | €376.45M | €320.40M | €60.36M | €60.36M |
| Total Equity | €13.76B | €13.53B | €14.20B | €14.28B | €14.28B |
| Stockholders' Equity | €12.79B | €12.56B | €13.24B | €13.31B | €13.31B |
| Capital Stock | €268.56M | €268.56M | €293.41M | €293.41M | €293.41M |
| -Common Stock | €268.56M | €268.56M | €293.41M | €293.41M | €293.41M |
| Additional Paid-In Capital | €1.88B | €1.60B | €3.03B | €3.08B | €3.08B |
| Retained Earnings | €12.23B | €12.09B | €12.30B | €12.21B | €12.21B |
| Less: Treasury Stock | -€357.12M | -€93.79M | -€940.59M | -€586.09M | -€586.09M |
| Gains/Losses Not Affecting Retained Earnings | -€1.22B | -€1.31B | -€1.44B | -€1.68B | -€1.68B |
| Minority Interests | €964.81M | €974.54M | €962.89M | €972.98M | €972.98M |
| -Loans Receivable | – | – | – | €953,000.00 | €953,000.00 |
| -Notes Receivable | – | – | – | €65.42M | €65.42M |
| -Accrued Interest Receivable | – | – | – | €21.40M | €21.40M |
| -Other Receivables | – | – | – | €292.88M | €292.88M |
| -Receivables Adjustments Allowances | – | – | – | -€207.68M | -€207.68M |
| Prepaid Assets | – | – | – | €23.32M | €23.32M |
| Restricted Cash | – | – | – | €16.60M | €16.60M |
| -Accumulated Depreciation | – | – | – | -€11.18B | -€11.18B |
| -Held to Maturity Securities | – | – | – | €302.68M | €302.68M |
| -Other Payable | – | – | – | €238,000.00 | €238,000.00 |
| Current Accrued Expenses | – | – | – | €263.33M | €263.33M |
| Current Deferred Liabilities | – | – | – | €114.37M | €114.37M |
| Derivative Product Liabilities | – | – | – | €155.04M | €155.04M |
Cash flow
| Line item | 2026 Q3 (EUR) |
2026 Q2 (EUR) |
2026 Q1 (EUR) |
2025 ANNUAL (EUR) |
2025 Q4 (EUR) |
|---|---|---|---|---|---|
| Operating Cash Flow | €797.56M | €860.30M | €226.89M | €2.68B | €1.00B |
| Net cash flow from continuing operations | €797.56M | €860.30M | €226.89M | €2.68B | €1.00B |
| Net Income from Continuing Operations | €224.80M | €293.17M | €164.76M | €1.19B | €402.02M |
| Gain/Loss from Continuing Operations | -€25.34M | €37.16M | -€32.55M | -€58.13M | -€23.77M |
| Depreciation & Depletion & Amortization | €433.00M | €363.11M | €462.94M | €1.50B | €373.55M |
| Deferred Tax | -€63.68M | -€52.16M | -€10.28M | -€27.21M | €3.34M |
| Other Non-Cash Items | €81.46M | €82.86M | €78.68M | €314.80M | €85.40M |
| Change in Working Capital | €325.15M | €297.16M | -€358.04M | €138.24M | €152.90M |
| -Change in Receivables | €48.92M | €252.63M | -€382.18M | -€69.06M | €98.94M |
| -Change in Inventory | -€85.05M | -€17.25M | -€146.78M | -€248.66M | -€59.17M |
| -Change in Payables and Accrued Expense | €422.44M | €118.25M | €133.90M | €249.06M | -€74.24M |
| -Change in Other Current Assets | -€61.16M | -€56.47M | €37.02M | €206.90M | €187.38M |
| Net cash flow from investing | -€209.87M | -€270.76M | -€169.48M | -€722.53M | -€418.23M |
| Net Cash Flow from Continuing Investing Activities | -€209.87M | -€270.76M | -€169.48M | -€722.53M | -€418.23M |
| Net PPE Purchase and Sale | -€233.63M | -€235.35M | -€186.99M | -€898.67M | -€417.96M |
| Net Business Purchase and Sale | €10.46M | -€2.62M | -€3.13M | €180.17M | €35.26M |
| Net Investment Purchase and Sale | €13.30M | -€32.79M | €20.64M | -€4.02M | -€35.53M |
| Financing Cash Flow | -€564.56M | -€769.54M | -€436.09M | -€1.40B | -€208.39M |
| Net Cash Flow from Continuing Financing Activities | -€564.56M | -€769.54M | -€436.09M | -€1.40B | -€208.39M |
| Net Issuance Payments Of Debt | -€201.66M | -€147.03M | -€16.30M | €149.58M | €285.71M |
| Net Common Stock Issuance | -€284.18M | -€144.64M | -€347.33M | -€585.29M | -€434.17M |
| Cash Dividends Paid | €0.00 | – | – | -€422.52M | €0.00 |
| Net Other Financing Charges | -€78.72M | -€77.70M | -€72.45M | -€544.99M | -€59.93M |
| Ending Cash Balance | €1.10B | €1.06B | €1.24B | €1.60B | €1.60B |
| Net Change in Cash | €23.13M | -€180.00M | -€378.68M | €555.26M | €375.07M |
| Beginning Cash Balance | €1.06B | €1.24B | €1.60B | €1.19B | €1.26B |
| Effect of Exchange Rate Changes | €15.11M | €2.10M | €18.71M | -€141.48M | -€32.18M |
| Free Cash Flow | €559.59M | €619.90M | €36.82M | €1.77B | €578.67M |
No comments yet — be the first to weigh in on FMS.
Sign in to join the discussion.